Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dawn Aranguren"'
Autor:
Sarah M. Jenkins, Cristiane M. Ida, Dawn Aranguren, Alissa Caron, Grant M. Spears, Fausto J. Rodriguez, Caterina Giannini, Peter C. Burger, Daniel H. Lachance
Publikováno v:
Brain Pathology. 25:575-586
Prognostic significance of histological anaplasia and BRAF V600E mutation were retrospectively evaluated in 74 patients with pleomorphic xanthoastrocytoma (PXA). Median age at diagnosis was 21.5 years (31 pediatric, 43 adult) and median follow-up 7.6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73561e21a4e942b1c6bc6cb9cc52dbf9
https://doi.org/10.1111/bpa.12217
https://doi.org/10.1111/bpa.12217
Autor:
Farrah J. Mateen, James R. Jett, Ronald L. Richardson, Aminah Jatoi, Timothy W. Lineberry, Julian R. Molina, Gary A. Croghan, Dawn Aranguren, Randolph S. Marks, Edward T. Creagan
Publikováno v:
Psycho-Oncology. 17:721-725
Objective: Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia. Methods: This retrospective study focused on patients with pre-existing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b4f08a771fae9633ff34e55423b5320
https://doi.org/10.1002/pon.1303
https://doi.org/10.1002/pon.1303
Autor:
Aminah Jatoi, Dawn Aranguren
Publikováno v:
Journal of Thoracic Oncology. 2:83-90
Lung cancer remains the leading cause of cancer-related death in the United States, and, at the same time, the American population is getting older. These two factors have given rise to a greater focus on how best to treat non-small cell lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::378c9f3e42eafbd373a464174bf003d5
https://doi.org/10.1097/01243894-200701000-00018
https://doi.org/10.1097/01243894-200701000-00018
Autor:
Xu Shan Sun, Hale Basak Ozkok, Juliette Thariat, Yazici Gozde, Robert C. Miller, Marco Krengli, Onal Cem, Kaouthar Khanfir, Serap Akyurek, Pirus Ghadjar, Candan Demiroz, Dawn Aranguren, Sefik Igdem, Gabriela Studer
Publikováno v:
Journal of Clinical Oncology. 31:e17019-e17019
e17019 Background: To report the role of combined chemotherapy in SGT. Methods: 251 patients with SGC treated in 2001-2011 were included in a collaborative IRB-approved retrospective RCN study. Chemotherapy is empirically administered based on extrap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::626d30a8e460565aad4d20e1ea2d3372
https://doi.org/10.1200/jco.2013.31.15_suppl.e17019
https://doi.org/10.1200/jco.2013.31.15_suppl.e17019
Autor:
Dawn Aranguren, Araba A. Adjei, Sumithra J. Mandrekar, Lorelei J. Hanson, Brian Schwartz, Randolph S. Marks, Ronit Simantov, James R. Jett, Gary A. Croghan
Publikováno v:
Journal of Clinical Oncology. 23:3067-3067
3067 Background: Preclinical data in the A549 NSCLC xenograft model show that BAY 43–9006 (BAY) a dual-action Raf kinase and VEGFR inhibitor does not antagonize the effect of gefitinib. This phase I, single-center study was conducted to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce2724e3a2ca45b56d04a2e00af2c109
https://doi.org/10.1200/jco.2005.23.16_suppl.3067
https://doi.org/10.1200/jco.2005.23.16_suppl.3067